Download PDF

1. Company Snapshot

1.a. Company Description

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases.Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema.Adverum Biotechnologies, Inc.


has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek.The company was formerly known as Avalanche Biotechnologies, Inc.and changed its name to Adverum Biotechnologies, Inc.


in May 2016.Adverum Biotechnologies, Inc.was incorporated in 2006 and is headquartered in Redwood City, California.

Show Full description

1.b. Last Insights on ADVM

Adverum Biotechnologies' recent performance has been negatively impacted by a series of investor alerts and investigations into potential securities law violations. The company's disclosure of non-cash errors in its accounting for tenant improvement allowances associated with an operating lease and sublease has raised concerns among investors. Additionally, the company's decision to restate its previously issued financial statements has likely led to a loss of investor confidence. Furthermore, the ongoing investigations by law firms such as Pomerantz LLP and Bronstein, Gewirtz & Grossman, LLC have created uncertainty and volatility in the market.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly

Dec -01

Source: globenewswire.com

Card image cap

Halper Sadeh LLC Encourages CDTX, MRSN, HOLX Shareholders to Contact the Firm to Discuss Their Rights

Nov -14

Source: prnewswire.com

Card image cap

Adverum Biotechnologies (ADVM) Projected to Post Quarterly Earnings on Monday

Nov -01

Source: defenseworld.net

Card image cap

ADVM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Adverum Biotechnologies, Inc. Is Fair to Shareholders

Oct -27

Source: businesswire.com

Card image cap

Adverum Biotechnologies Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adverum Biotechnologies, Inc. - ADVM

Oct -25

Source: businesswire.com

Card image cap

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of MidWestOne Financial Group, Inc. (NASDAQ: MOFG)

Oct -24

Source: prnewswire.com

Card image cap

Shareholder Alert: The Ademi Firm investigates whether Adverum Biotechnologies, Inc. is obtaining a Fair Price for its Public Shareholders

Oct -24

Source: prnewswire.com

Card image cap

Eli Lilly to buy gene therapy developer Adverum in about $262 million deal

Oct -24

Source: reuters.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (11.30%)

6. Segments

Gene Therapeutics

Expected Growth: 11.3%

Adverum Biotechnologies' 11.3% growth in Gene Therapeutics is driven by increasing demand for novel treatments, advancements in gene editing technologies, and strategic partnerships. The company's focus on rare genetic diseases and ophthalmology also contributes to growth, as well as investments in research and development to expand its pipeline.

7. Detailed Products

ADVM-022

Gene therapy for the treatment of inherited retinal diseases

ADVM-032

Gene therapy for the treatment of alpha-1 antitrypsin deficiency

ADVM-043

Gene therapy for the treatment of Pompe disease

ADVM-053

Gene therapy for the treatment of Friedreich's ataxia

8. Adverum Biotechnologies, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Adverum Biotechnologies, Inc. has a low threat of substitutes due to its unique gene therapy products and limited availability of alternative treatments for inherited retinal diseases.

Bargaining Power Of Customers

Adverum Biotechnologies, Inc. has a medium bargaining power of customers due to the limited number of buyers and the company's focus on rare genetic diseases, which gives customers some negotiating power.

Bargaining Power Of Suppliers

Adverum Biotechnologies, Inc. has a low bargaining power of suppliers due to its reliance on a few key suppliers for raw materials and manufacturing services, but the company's small size and niche market reduce its negotiating power.

Threat Of New Entrants

Adverum Biotechnologies, Inc. faces a high threat of new entrants due to the growing interest in gene therapy and the increasing number of biotech companies entering the market, which could lead to increased competition.

Intensity Of Rivalry

Adverum Biotechnologies, Inc. operates in a moderately competitive market with a few established players, but the company's focus on rare genetic diseases and its unique products reduce the intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 47.34%
Debt Cost 3.95%
Equity Weight 52.66%
Equity Cost 8.35%
WACC 6.27%
Leverage 89.90%

11. Quality Control: Adverum Biotechnologies, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
aTyr Pharma

A-Score: 4.6/10

Value: 7.6

Growth: 6.4

Quality: 6.8

Yield: 0.0

Momentum: 5.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Veracyte

A-Score: 4.3/10

Value: 1.2

Growth: 8.4

Quality: 6.4

Yield: 0.0

Momentum: 6.0

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
Alector

A-Score: 2.8/10

Value: 7.8

Growth: 3.7

Quality: 3.7

Yield: 0.0

Momentum: 1.0

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Recursion Pharmaceuticals

A-Score: 2.8/10

Value: 6.8

Growth: 3.9

Quality: 3.4

Yield: 0.0

Momentum: 2.0

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Codexis

A-Score: 2.7/10

Value: 7.0

Growth: 0.7

Quality: 3.9

Yield: 0.0

Momentum: 3.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Adverum Biotechnologies

A-Score: 2.6/10

Value: 8.0

Growth: 1.9

Quality: 3.6

Yield: 0.0

Momentum: 1.0

Volatility: 1.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

4.26$

Current Price

4.26$

Potential

-0.00%

Expected Cash-Flows